Cyclophosphamide and tucotuzumab (huKS-IL2) following first-line chemotherapy in responding patients with extensive-disease small-cell lung cancer.

The humanized KS-interleukin-2, tucotuzumab (huKS-IL2; EMD 273066), is an EpCAM-specific immunocytokine with reported immunologic activity in combination with cyclophosphamide. This Phase 2, randomized, open-label study compared tucotuzumab/cyclophosphamide, administered as maintenance, with best supportive care (BSC) in patients with extensive-disease small-cell lung cancer (ED-SCLC) who responded to first-line platinum-based chemotherapy with/without prophylactic cranial irradiation (PCI). Patients received cyclophosphamide (300 mg/m, Day 1 of every 3-week cycle), followed by tucotuzumab (1.

[The role of symptoms of neurological deficit in diagnostics of sarcoidosis--a description of two cases].

Sarcoidosis, systemic inflammatory disease, may involve the nervous system and muscles.Typical symptoms and signs of neurological deficit suggest considering sarcoidosis in differential diagnostics of their background. The authors describe two cases, in which involvement of the nervous system or muscles contributed to the direction of further diagnostics and approaching the diagnosis of sarcoidosis.